111 related articles for article (PubMed ID: 7630637)
21. Transcriptional activation potential of normal and tumor-associated myb isoforms does not correlate with their ability to block GCSF-induced terminal differentiation of murine myeloid precursor cells.
Patel G; Tantravahi R; Oh IH; Reddy EP
Oncogene; 1996 Sep; 13(6):1197-208. PubMed ID: 8808694
[TBL] [Abstract][Full Text] [Related]
22. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
23. Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells.
Gudas JM; Klein RC; Oka M; Cowan KH
Clin Cancer Res; 1995 Feb; 1(2):235-43. PubMed ID: 9815978
[TBL] [Abstract][Full Text] [Related]
24. Solution structure of the B-Myb DNA-binding domain: a possible role for conformational instability of the protein in DNA binding and control of gene expression.
McIntosh PB; Frenkiel TA; Wollborn U; McCormick JE; Klempnauer KH; Feeney J; Carr MD
Biochemistry; 1998 Jul; 37(27):9619-29. PubMed ID: 9657674
[TBL] [Abstract][Full Text] [Related]
25. Human c-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter.
Nürnberg W; Artuc M; Nawrath M; Lovric J; Stüting S; Moelling K; Czarnetzki BM; Schadendorf D
Cancer Res; 1995 Oct; 55(19):4432-7. PubMed ID: 7671256
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional regulation by the carboxyl terminus of c-Myb depends upon both the Myb DNA-binding domain and the DNA recognition site.
Dubendorff JW; Lipsick JS
Oncogene; 1999 Jun; 18(23):3452-60. PubMed ID: 10376523
[TBL] [Abstract][Full Text] [Related]
27. Nitric oxide-releasing agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and suppress erythroid-specific gene expression: correlation with decreased DNA binding of NF-E2 and altered c-myb mRNA expression.
Suhasini M; Boss GR; Pascual FE; Pilz RB
Cell Growth Differ; 1995 Dec; 6(12):1559-66. PubMed ID: 9019161
[TBL] [Abstract][Full Text] [Related]
28. Redundant functions of B-Myb and c-Myb in differentiating myeloid cells.
Golay J; Broccoli V; Borleri GM; Erba E; Faretta M; Basilico L; Ying GG; Piccinini G; Shapiro LH; Lovrić J; Nawrath M; Mölling K; Rambaldi A; Introna M
Cell Growth Differ; 1997 Dec; 8(12):1305-16. PubMed ID: 9419419
[TBL] [Abstract][Full Text] [Related]
29. Murine myeloid leukemias with aberrant myb loci show heterogeneous expression of novel myb proteins.
Dudek H; Reddy EP
Oncogene; 1989 Dec; 4(12):1489-95. PubMed ID: 2480562
[TBL] [Abstract][Full Text] [Related]
30. The A-myb gene is preferentially expressed in tonsillar CD38+, CD39-, and sIgM- B lymphocytes and in Burkitt's lymphoma cell lines.
Golay J; Erba E; Bernasconi S; Peri G; Introna M
J Immunol; 1994 Jul; 153(2):543-53. PubMed ID: 8021494
[TBL] [Abstract][Full Text] [Related]
31. Tumorigenic N-terminal deletions of c-Myb modulate DNA binding, transactivation, and cooperativity with C/EBP.
Oelgeschläger M; Kowenz-Leutz E; Schreek S; Leutz A; Lüscher B
Oncogene; 2001 Nov; 20(50):7420-4. PubMed ID: 11704872
[TBL] [Abstract][Full Text] [Related]
32. Differential splicing of the mouse B-myb gene.
Kamano H; Burk B; Noben-Trauth K; Klempnauer KH
Oncogene; 1995 Dec; 11(12):2575-82. PubMed ID: 8545114
[TBL] [Abstract][Full Text] [Related]
33. Alternative splicing of the human c-myb gene.
Westin EH; Gorse KM; Clarke MF
Oncogene; 1990 Aug; 5(8):1117-24. PubMed ID: 2202948
[TBL] [Abstract][Full Text] [Related]
34. Proto-oncogene expression in chicken leukemic cells induced by avian myeloblastosis virus.
Kim WK; Baluda MA
Oncogene Res; 1988 Sep; 3(2):147-54. PubMed ID: 3226723
[TBL] [Abstract][Full Text] [Related]
35. High affinity DNA binding of native full length c-Myb and differential proteolytic sensitivity of its N- and C-terminal domains.
Krieg J; Oelgeschläger M; Janknecht R; Lüscher B
Oncogene; 1995 Jun; 10(11):2221-8. PubMed ID: 7784067
[TBL] [Abstract][Full Text] [Related]
36. GATA-1 and c-myb crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myb promoter.
Bartůnek P; Králová J; Blendinger G; Dvorák M; Zenke M
Oncogene; 2003 Apr; 22(13):1927-35. PubMed ID: 12673198
[TBL] [Abstract][Full Text] [Related]
37. The human A-myb protein is a strong activator of transcription.
Golay J; Loffarelli L; Luppi M; Castellano M; Introna M
Oncogene; 1994 Sep; 9(9):2469-79. PubMed ID: 8058310
[TBL] [Abstract][Full Text] [Related]
38. An alternatively spliced isoform of B-Myb is a transcriptional inhibitor.
Horstmann S; Ferrari S; Klempnauer KH
Oncogene; 2000 Nov; 19(48):5428-34. PubMed ID: 11114719
[TBL] [Abstract][Full Text] [Related]
39. Nuclear and cytoplasmic distribution of cellular myb protein in human haematopoietic cells evidenced by monoclonal antibody.
Bading H; Gerdes J; Schwarting R; Stein H; Moelling K
Oncogene; 1988 Sep; 3(3):257-65. PubMed ID: 3060791
[TBL] [Abstract][Full Text] [Related]
40. Characterization of alternate and truncated forms of murine c-myb proteins.
Ramsay RG; Ishii S; Nishina Y; Soe G; Gonda TJ
Oncogene Res; 1989; 4(4):259-69. PubMed ID: 2549488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
